These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

537 related items for PubMed ID: 12882909

  • 1. Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients.
    Miyazaki Y, He H, Mandarino LJ, DeFronzo RA.
    Diabetes; 2003 Aug; 52(8):1943-50. PubMed ID: 12882909
    [Abstract] [Full Text] [Related]

  • 2. Activation of protein kinase C-zeta by insulin and phosphatidylinositol-3,4,5-(PO4)3 is defective in muscle in type 2 diabetes and impaired glucose tolerance: amelioration by rosiglitazone and exercise.
    Beeson M, Sajan MP, Dizon M, Grebenev D, Gomez-Daspet J, Miura A, Kanoh Y, Powe J, Bandyopadhyay G, Standaert ML, Farese RV.
    Diabetes; 2003 Aug; 52(8):1926-34. PubMed ID: 12882907
    [Abstract] [Full Text] [Related]

  • 3. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.
    Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, Cusi K, Mandarino LJ, DeFronzo RA.
    Diabetes Care; 2001 Apr; 24(4):710-9. PubMed ID: 11315836
    [Abstract] [Full Text] [Related]

  • 4. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients.
    Miyazaki Y, Glass L, Triplitt C, Matsuda M, Cusi K, Mahankali A, Mahankali S, Mandarino LJ, DeFronzo RA.
    Diabetologia; 2001 Dec; 44(12):2210-9. PubMed ID: 11793023
    [Abstract] [Full Text] [Related]

  • 5. Rosiglitazone reverses insulin secretion altered by chronic exposure to free fatty acid via IRS-2-associated phosphatidylinositol 3-kinase pathway.
    Yang L, An HX, Deng XL, Chen LL, Li ZY.
    Acta Pharmacol Sin; 2003 May; 24(5):429-34. PubMed ID: 12740178
    [Abstract] [Full Text] [Related]

  • 6. Insulin signal transduction in skeletal muscle from glucose-intolerant relatives of type 2 diabetic patients [corrected].
    Storgaard H, Song XM, Jensen CB, Madsbad S, Björnholm M, Vaag A, Zierath JR.
    Diabetes; 2001 Dec; 50(12):2770-8. PubMed ID: 11723060
    [Abstract] [Full Text] [Related]

  • 7. Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients.
    Bajaj M, Suraamornkul S, Romanelli A, Cline GW, Mandarino LJ, Shulman GI, DeFronzo RA.
    Diabetes; 2005 Nov; 54(11):3148-53. PubMed ID: 16249438
    [Abstract] [Full Text] [Related]

  • 8. Skeletal muscle insulin resistance in normoglycemic subjects with a strong family history of type 2 diabetes is associated with decreased insulin-stimulated insulin receptor substrate-1 tyrosine phosphorylation.
    Pratipanawatr W, Pratipanawatr T, Cusi K, Berria R, Adams JM, Jenkinson CP, Maezono K, DeFronzo RA, Mandarino LJ.
    Diabetes; 2001 Nov; 50(11):2572-8. PubMed ID: 11679436
    [Abstract] [Full Text] [Related]

  • 9. Thiazolidinediones improve beta-cell function in type 2 diabetic patients.
    Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA.
    Am J Physiol Endocrinol Metab; 2007 Mar; 292(3):E871-83. PubMed ID: 17106061
    [Abstract] [Full Text] [Related]

  • 10. Thiazolidinedione treatment prevents free fatty acid-induced insulin resistance in male wistar rats.
    Hevener AL, Reichart D, Janez A, Olefsky J.
    Diabetes; 2001 Oct; 50(10):2316-22. PubMed ID: 11574414
    [Abstract] [Full Text] [Related]

  • 11. Dissociation between fat-induced in vivo insulin resistance and proximal insulin signaling in skeletal muscle in men at risk for type 2 diabetes.
    Storgaard H, Jensen CB, Björnholm M, Song XM, Madsbad S, Zierath JR, Vaag AA.
    J Clin Endocrinol Metab; 2004 Mar; 89(3):1301-11. PubMed ID: 15001626
    [Abstract] [Full Text] [Related]

  • 12. Thiazolidinediones increase hepatic insulin extraction in African Americans with impaired glucose tolerance and type 2 diabetes mellitus. A pilot study of rosiglitazone.
    Osei K, Gaillard T, Schuster D.
    Metabolism; 2007 Jan; 56(1):24-9. PubMed ID: 17161222
    [Abstract] [Full Text] [Related]

  • 13. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.
    Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, Mandarino LJ, DeFronzo RA.
    J Clin Endocrinol Metab; 2002 Jun; 87(6):2784-91. PubMed ID: 12050251
    [Abstract] [Full Text] [Related]

  • 14. Effects of exercise and insulin on insulin signaling proteins in human skeletal muscle.
    Koval JA, Maezono K, Patti ME, Pendergrass M, DeFronzo RA, Mandarino LJ.
    Med Sci Sports Exerc; 1999 Jul; 31(7):998-1004. PubMed ID: 10416561
    [Abstract] [Full Text] [Related]

  • 15. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects.
    Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M, Olefsky JM.
    Diabetes; 2002 Oct; 51(10):2968-74. PubMed ID: 12351435
    [Abstract] [Full Text] [Related]

  • 16. Ursolic acid and rosiglitazone combination improves insulin sensitivity by increasing the skeletal muscle insulin-stimulated IRS-1 tyrosine phosphorylation in high-fat diet-fed C57BL/6J mice.
    Sundaresan A, Radhiga T, Pugalendi KV.
    J Physiol Biochem; 2016 Jun; 72(2):345-52. PubMed ID: 27090933
    [Abstract] [Full Text] [Related]

  • 17. Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.
    Triplitt C, Glass L, Miyazaki Y, Wajcberg E, Gastaldelli A, De Filippis E, Cersosimo E, DeFronzo RA.
    Diabetes Care; 2006 Nov; 29(11):2371-7. PubMed ID: 17065670
    [Abstract] [Full Text] [Related]

  • 18. Rosiglitazone ameliorates abnormal expression and activity of protein tyrosine phosphatase 1B in the skeletal muscle of fat-fed, streptozotocin-treated diabetic rats.
    Wu Y, Ouyang JP, Wu K, Wang SS, Wen CY, Xia ZY.
    Br J Pharmacol; 2005 Sep; 146(2):234-43. PubMed ID: 15997237
    [Abstract] [Full Text] [Related]

  • 19. Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability.
    Oakes ND, Thalén PG, Jacinto SM, Ljung B.
    Diabetes; 2001 May; 50(5):1158-65. PubMed ID: 11334421
    [Abstract] [Full Text] [Related]

  • 20. Dose-response effect of elevated plasma free fatty acid on insulin signaling.
    Belfort R, Mandarino L, Kashyap S, Wirfel K, Pratipanawatr T, Berria R, Defronzo RA, Cusi K.
    Diabetes; 2005 Jun; 54(6):1640-8. PubMed ID: 15919784
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.